Hanna Erin M, Martinie John B, Swan Ryan Z, Iannitti David A
Division of Hepatobiliary and Pancreatic Surgery, Department of General Surgery, Carolinas Medical Center, 1025 Moorehead Medical Drive, Suite 600, Charlotte, NC, 28204, USA.
Langenbecks Arch Surg. 2014 Oct;399(7):825-35. doi: 10.1007/s00423-014-1215-5. Epub 2014 Jun 2.
Fibrin sealants and topical hemostatic agents have been used extensively in hepatobiliary and pancreatic (HPB) surgery to promote coagulation and clot formation decreasing the need for allogeneic blood transfusion and to act as tissue sealants, ideally preventing biliary, enteric, and pancreatic leaks.
Current literature has demonstrated some favorable outcomes using many different products for application in the field of HPB surgery. However, critical findings exist demonstrating lack of reproducible efficacy or benefit. In all, many clinical trials have demonstrated effectiveness of fibrin sealants and other agents at reducing the need for intraoperative and postoperative blood transfusion. Ability to effectively seal tissues providing biliostatic effect or preventing postoperative fistula formation remains debated as definitive evidence is lacking.
In the following invited review, we discuss current literature describing the use of topical agents and fibrin sealants in liver and pancreas surgery. We summarize major contemporary clinical trials and their findings regarding the use of these agents in HPB surgery and provide evidence from the preclinical literature as to the translation of these products into the clinical arena.
纤维蛋白封闭剂和局部止血剂已在肝胆胰(HPB)手术中广泛应用,以促进凝血和血栓形成,减少异体输血需求,并作为组织封闭剂,理想情况下可预防胆漏、肠漏和胰漏。
当前文献表明,在HPB手术领域使用许多不同产品取得了一些良好效果。然而,也存在关键发现显示缺乏可重复的疗效或益处。总体而言,许多临床试验已证明纤维蛋白封闭剂和其他药物在减少术中及术后输血需求方面的有效性。由于缺乏确凿证据,其有效封闭组织以提供胆汁抑制作用或预防术后瘘形成的能力仍存在争议。
在以下特邀综述中,我们讨论了描述局部用药和纤维蛋白封闭剂在肝脏和胰腺手术中应用的当前文献。我们总结了当代主要临床试验及其在HPB手术中使用这些药物的研究结果,并提供临床前文献中关于这些产品转化到临床领域的证据。